Showing 9511-9520 of 18069 results for "".
- Evolving Insights into Depression's Role in Dementia Prevention for Aging Populationshttps://reachmd.com/news/evolving-insights-into-depressions-role-in-dementia-prevention-for-aging-populations/2474908/Emerging epidemiological data indicate that individuals with midlife depression face an increased risk of dementia, with a hazard ratio of 1.19 for all-cause de
- Optimizing Nutritional Interventions Post-Discharge for Critically Ill Childrenhttps://reachmd.com/news/optimizing-nutritional-interventions-post-discharge-for-critically-ill-children/2474912/Emerging data reveals that addressing nutritional deficits at hospital discharge is associated with improved recovery and outcomes for critically ill children, with a decline in nutritional status post-discharge linked to adverse clinical tra
- Expanding Horizons: The Role of Advanced MRI and Integrative Metrics in Child Neurologyhttps://reachmd.com/news/expanding-horizons-the-role-of-advanced-mri-and-integrative-metrics-in-child-neurology/2474926/Child neurologists and general pediatricians face mounting pressure to detect neurological disorders at the earliest stages, yet diagnostic blind spots in traditional imaging can delay crucial interventions during sensitive periods of brain d
- Addressing Diagnostic Blind Spots in Pulmonary Imaging with AI and Advanced Techniqueshttps://reachmd.com/news/addressing-diagnostic-blind-spots-in-pulmonary-imaging-with-ai-and-advanced-techniques/2474918/Underrecognized diagnostic blind spots in pulmonary imaging, particularly with subsolid nodules like ground-glass opacities, can delay critical inte
- Advancing Inflammatory Bowel Disease Treatment: Mirikizumab and AI Innovationshttps://reachmd.com/news/advancing-inflammatory-bowel-disease-treatment-mirikizumab-and-ai-innovations/2474917/An escalating demand for innovative treatment and diagnostic options in inflammatory bowel disease underscores the urgency for new approaches, as therapeutic agents like mirikizumab and AI-powered tools begin reshaping IBD management today.</
- The Role of sCD13 in Inflammation: Linking Autoimmune Disorders and COVID-19https://reachmd.com/news/the-role-of-scd13-in-inflammation-linking-autoimmune-disorders-and-covid-19/2474856/Emerging evidence underscores the critical role of sCD13 in modulating inflammatory responses, influencing chronic autoimmune disorders like rheumatoid arthritis and acute infections such as COVID-19. This article explores the mechanisms by which sCD13 drives inflammation a
- Evolving Strategies for Lupus Nephritis: Integrating Precision in Treatmenthttps://reachmd.com/news/evolving-strategies-for-lupus-nephritis-integrating-precision-in-treatment/2474857/Lupus nephritis remains among the most challenging manifestations of systemic lupus erythematosus, demanding vigilant assessment and a shift toward more precise, individualized treatment paradigms. Despite recent nephrology advancement
- Maternal Selenium Levels and Reduced Childhood Streptococcal Infectionshttps://reachmd.com/news/maternal-selenium-levels-and-reduced-childhood-streptococcal-infections/2474851/Observational evidence shows an association between elevated maternal selenium levels and a lower prevalence of childhood streptococcal infections. These insights have the potential to inform prenatal nutritional recommendations and ped
- Emerging Trends in Regional Anesthesia: Balancing Innovation with Safetyhttps://reachmd.com/news/emerging-trends-in-regional-anesthesia-balancing-innovation-with-safety/2474905/Emerging trends in regional anesthesia are rapidly reshaping acute pain management, compelling anesthesiologists to integrate advanced techniques with uncompromising safety protocols, while also considering potential risks and challenges asso
- Zasocitinib Effective in TYK2 Inhibition for Inflammatory Skin Disease: Studyhttps://reachmd.com/news/zasocitinib-effecgive-in-tyk2-inhibition-for-inflammatory-skin-disease/2474891/Zasocitinib, billed as a 'next-generation' therapy, showed pharmacologic potency and high specificity compared to Janus and other kinase inhibitors, according to new results published in the Journal of Investigative Dermatology</